Description
Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. (source: http://en.wikipedia.org/wiki/Tofacitinib).
Synonyms
CP-690550; CP 690550; CP690550; Tofacitinib; tasocitinib.
IUPAC Name
2-hydroxypropane-1,2,3-tricarboxylic acid;3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
Molecular Formula
C22H28N6O8
Canonical SMILES
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
InChI
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
InChIKey
SYIKUFDOYJFGBQ-YLAFAASESA-N
Melting Point
198-202 °C (dec.)
Solubility
In Vitro:
DMSO : ≥ 122.5 mg/mL (242.82 mM)
H2O : 5 mg/mL (9.91 mM; Need ultrasonic and warming)
Appearance
White to Off-white Solid
Application
Janus Kinase Inhibitors